FX8863
New product
Quantity | Discount | |
---|---|---|
2 | 5% | |
3 | 10% | |
4 | 15% | |
5 | 20% |
Warning: Last items in stock!
Availability date:
Quantity | Discount | You Save |
---|---|---|
2 | 5% | Up to $2.90 |
3 | 10% | Up to $8.70 |
4 | 15% | Up to $17.40 |
5 | 20% | Up to $29.00 |
Market Shapes:
1 ampoule 1 ampoule
Usage:
It is adjusted according to the individual's treatment. In adults 20-40 mg i.m. every 2-4 weeks. .
Indications:
Antipsychotic, anxiolytic neuroleptic. It is especially indicated for the treatment of idiopathic schizophrenia and other psychoses with hallucinations, delusions and distress symptoms accompanied by apathy, anger, depression and withdrawal.
Contraindications:
Acute alcohol, barbiturates and opiate poisonings are contraindicated in coma. It should not be applied in excitable or overactive patients, as the activating effect of the drug may exacerbate such properties.
Warnings:
Advanced liver, convulsive or cardiovascular disease, as well as severe respiratory disease, renal insufficiency and Parkinson's disease should be administered with caution. When the sedative effect is initiated with flupentixol therapy in cases of treatment with prominent neuroleptics, the dose of this neuroleptic should be reduced and reduced. Cases that are treated with long-lasting and especially high doses should be carefully monitored and periodically assessed to determine the dosing dose. Malignant neuroleptic syndrome is a rare condition that can carry fatal potential due to the use of neuroleptics. The main indications of the MNS are hyperthermia, muscle rigidity, and fluctuating consciousness as well as autonomic dysfunctions (lavage blood pressure, tachycardia, diaphoresis). In addition to the necessity of immediate interruption of the neuroleptic drug, general supportive measures and symptomatic treatment are essential. Preferably they should not be given during pregnancy and lactation. Not used in children. The ability to drive and machine can be affected during treatment. For this reason, care must be taken as far as determining the answer to which the individual will give treatment.
Side effects:
Estropyramidal symptoms may occur during the treatment of flupentixol, especially in the early phases of treatment. In many cases, such side effects can be controlled satisfactorily by dosage reduction and / or antiparkinsonian drugs. However, routine, prophylactic administration of antiparkinsonian drugs is not recommended. Tardive dyskinesia may occur very rarely in long-term therapy, but antiparkinsonian therapy has no effect on these symptoms. In this condition it may be useful to reduce the treatment dose and, if possible, to discontinue it. Very rarely, it can cause temporary insomnia, especially when it is switched from sedative neuroleptics to flupenthix. A sedative effect may occur at high doses. Slight elevations can be detected in liver function tests.
Drug Interactions:
Flupentixol increases the response to alcohol and barbiturates and other central nervous system depressants at high doses. Flupentixol should not be administered with drugs that have guanethidine or similar effects as they may block antihypertensive effects. In addition, it may reduce the effects of levodopa or adrenergic drugs, as well as the use of metoclopramide or piperazine increases the risk of developing extrapyramidal symptoms.